Murepavadin is the first product Polyphor developed in a new class of antibiotics known as Outer Membrane Protein Targeting Antibiotics (OMPTA) in a move to target increasing resistance to antibiotics.
It specifically targets Pseudomonas aeruginosa (PA), one of the most antibiotic-resistant pathogens. PA is the main cause of chronic lung infections in patients with cystic fibrosis, explained Giacomo Di Nepi, CEO of Polyphor, in a statement.
Administered by the airwaves, Murepavadin would facilitate targeted treatment and is thus being developed in an inhaled formulation.
Polyphor is also supporting the European consortium iABC, which is dedicated to the development of inhaled antibiotics. Lung specialists from 18 hospitals and research institutes across eight European countries are participating.
The Basel-based pharmaceutical company Novartis is joining Polyphor as an industrial partner of the project.
Funding of 5 million euros is being provided by the public-private partnership Innovative Medicine Initiative (IMI), which was launched by the EU and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Polyphor will also support iABC with 5 million euros.
“We are pleased and honored to be selected as one of two industry partners of the iABC consortium,” commented Di Nepi in the statement. He explained that by targeting only Pseudomonas aeruginosa, Murepavadin does not induce further resistance in other pathogens.
He added: “Murepavadin may therefore provide a new important treatment option for patients with cystic fibrosis and bronchiectasis."